Fact CheckerSign in

NCT06489119Recruiting

Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)

Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease - a Prospective, Observational Study

Source: ClinicalTrials.gov · Last updated 15 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The MOOP-CAD study program characterizes, for the first time, the pathophysiological processes and molecular mechanisms of coronary atherosclerotic plaque progression by combining in vivo intravascular imaging techniques with circulating immune single-cell multi-omics analysis. In this study, the investigators evaluate the imaging characteristics of coronary plaques by optical coherence tomography (OCT) and invasive angiography, and study the correlation between plaque characteristics and the multi-omics immune characteristic profiles.

Status (registry)
Recruiting
Study type
Observational
Enrollment
350 (estimated)
First submitted
17 Jun 2024
Start date
7 Jul 2024
Primary completion date
15 Jan 2026
Lead sponsor
Harbin Medical University
NCT number
NCT06489119

What you commit to

  • Study type: Observational
  • Planned participants: 350
  • From 7 Jul 2024 to the primary completion date, 15 Jan 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with organ transplants or patients on the waiting list for an organ transplant.
  • Previous CABG treatment, PCI treatment of the target vessel, and PCI treatment of non-target vessels within 1 year.

Other illness

  • Cardiogenic shock or circulatory depression,life-threatening arrhythmia.
  • Severe systemic diseases (end-stage renal disease, serious liver dysfunction, chronic active inflammatory diseases, active oncologic diseases, autoimmune diseases).

Lab values

  • Known systolic heart failure with LVEF ≤30%.

Other

  • Septicemia, acute inflammatory event with fever.
  • Thrombolysis before PCI.
  • Stenosis of the left main artery ≥50%.
  • Characteristics rendering high-quality OCT imaging unlikely such as chronic total occlusion, pronounced tortuosity, heavily calcified vessels.
  • Infarcted vessel with a diameter \>4mm or \<2.5mm.
  • "No-reflow" (TIMI 0-1) after thrombus aspiration or predilatation.
  • Other subjects deemed unsuitable for study by investigators.

Who the study is looking for

  • Male or female, Age ≥ 18 years and ≤ 85 years.
  • Ability to understand the requirements of the study and to provide informed consent.
    • Control group:
    • Patients with coronary angiographic diameter stenosis \<20%.
    • Stable plaque group:
  • Have been clinically stable for at least 6 months.
  • Presence of ≥1 lesion with angiographic diameter stenosis \>50% with no TCFA lesions in the most severely narrowed native coronary artery (target vessel). TCFA was defined as a lipidic plaque with the thinnest FCT \<75 mm and maximum lipid arc \>180°.
  • Rule out elevation of troponin or myocardial enzymology.
    • Vulnerable plaque group:
  • Have been clinically stable for at least 6 months.
  • Presence of ≥1 lesion with angiographic diameter stenosis \>50% with TCFA lesions in the most severely narrowed native coronary artery (target vessel).
  • Rule out elevation of troponin or myocardial enzymology.
    • Plaque rupture group:
  • Persistent chest pain for 30 minutes, arrival at the hospital within 24 hours from symptom onset. ST-segment elevation of \>0.1 mV in ≥2 contiguous leads or new-onset left bundle branch block, and high sensitive Troponin T or I or CK/CK-MB above upper reference value.
  • Exist clearly identified culprit lesion.
  • Plaque rupture was defined by the presence of a discontinuity of the fibrous cap with a cavity formed inside the plaque.
    • Plaque erosion group:
  • Persistent chest pain for 30 minutes, arrival at the hospital within 24 hours from symptom onset. ST-segment elevation of \>0.1 mV in ≥2 contiguous leads or new-onset left bundle branch block, and high sensitive Troponin T or I or CK/CK-MB above upper reference value.
  • Exist clearly identified culprit lesion.
  • Plaque erosion was defined by the presence of the attached thrombus overlying the intact fibrous cap of the atherosclerotic plaque, luminal surface irregularity at the culprit lesion in the absence of thrombus, or attenuation of the underlying plaque by thrombus without superficial lipid or calcium at the site of the thrombus.

Age in the registry: 18 years to 85 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
China-Japan Union Hospital of Jilin
Coordinator of this site? Confirm its status
ChangchunChinaRecruiting
The Second Affiliated Hospital of Harbin Medical University
Coordinator of this site? Confirm its status
HarbinChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.